Most patients with BCS complicated by IVC thrombosis have a chronic disease course. Manifestations of thrombus formation are often concealed by the clinical manifestations of IVC obstruction. Therefore, the time at which thrombus formation occurs (acute, subacute, or chronic) is not clear. Thrombus formation is a dynamic process. Fresh thrombus evolves gradually (not suddenly) into old thrombus, so there is a type of thrombotic state (mixed), between fresh and old thrombus. Based on imaging features and transcatheter aspiration, IVC thrombus can be divided into fresh, mixed, and old types. Endovascular treatment strategies should be adopted according to the properties of thrombus, which can result in excellent long-term patency.
INTRODUCTION
BuddeChiari syndrome (BCS) refers to occlusion of any part of the outflow tract of the hepatic vein, from small hepatic veins to the confluence of the inferior vena cava (IVC) and right atrium. 1 In western countries, BCS mainly involves occlusion of the hepatic vein. 2 In China, it mainly involves occlusion of the IVC with or without hepatic vein occlusion. 3 The incidence of BCS complicated by IVC thrombosis in a single center in China has been reported to be 5%. 4 Methods for treating BCS complicated by IVC thrombosis include the use of warfarin, transcatheter thrombolysis using urokinase, stent placement, and stent filter placement. 5e7 However, there have been only few studies in which thrombi are categorized into fresh thrombus, mixed thrombus, and old thrombus, which are then treated accordingly. In addition, until now the long-term outcome of BCS complicated by IVC thrombosis after endovascular treatment has remained unclear. In this study the endovascular treatment strategies for patients with BCS complicated by IVC thrombosis and their long-term outcomes are reported. The large number of patients included in this study made it possible to establish routine treatment methods and to determine the risk factors that might predict reocclusion.
MATERIAL AND METHODS

Patient information
This was a retrospective study. All protocols were approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical College (Jiangsu Province, China). All the participating patients gave informed consent before endovascular treatment.
From February 2003 to March 2013, a total of 133 patients (80 males and 53 females) with primary BCS complicated by IVC thrombosis were included in this study. The average age was 48 (18e78) years. Patients with contraindications to anticoagulation, severe hepatic failure or heart failure were excluded. All 133 patients were diagnosed using color Doppler ultrasound, magnetic resonance angiography and/or computer tomography angiography, IVC angiography, and aspiration of the IVC thrombus. Among them, there were 75 cases of fresh thrombus, 19 cases of mixed thrombus, and 39 cases of old thrombus. All 133 patients had the symptoms and signs of IVC obstruction for 1e240 months. Initial patient demographic information before endovascular treatment was obtained from medical records for this retrospective analysis (Table 1) .
Procedures
The treatment steps for IVC occlusion complicated by thrombus are illustrated in Fig. 1 and are as the follows:
Step 1. IVC angiography and transcatheter aspiration. A 6F catheter sheath was placed in the femoral vein, and a 5F pigtail catheter was advanced into the IVC for contrast injection. The pigtail catheter was withdrawn and a 6F Judkins right guiding catheter (Cordis Corp., Hialeah, FL, USA) was advanced to the level of the IVC thrombus. The catheter was pushed back and forth and simultaneously rotated to facilitate aspiration of the thrombus. Selection of strategies for the subsequent treatments depended mainly on gross examination of the captured thrombus: (a) mixed thrombi, containing a large amount of gray-white thrombi and a small amount of dark red thrombi ( Fig. 2A,B) , were treated with a small balloon pre-dilation of the IVC (see Step 2); (b) fresh thrombus, that was dark red and soft, was treated with transcatheter thrombolysis (see Step 3); and (c) when no thrombus or only a small amount of white thrombus was obtained from the aspiration, it was determined to be an old thrombus and balloon dilation of the IVC was performed (see Step 4).
Step 2. Small balloon pre-dilation of the IVC. The jugular vein was punctured and a 6F catheter sheath was placed. A 5F angiographic catheter (Cordis Corp.) was advanced to the proximal end of the IVC to perform angiography. A steel needle with a curved head (China Patent No. 201120361170.4, the principal advantage of which is that the head-end can be curved to accommodate the shape of IVC), was advanced through the 5F angiographic catheter and penetrated the IVC occlusion from the top to the bottom end. The needle was withdrawn and a guidewire with length 260 cm and diameter 0.035 inches was advanced through the 5F angiographic catheter to the distal end of IVC. Next, the 5F catheter was withdrawn, and a smaller balloon with a diameter of 8 or 10 mm and a length of 40 mm (Cook Medical, Bjaeverskov, Denmark) was advanced along the guidewire to dilate the occluded segment of the IVC (Fig. 2CeE) . If the IVC occlusion could not be penetrated through the jugular vein, penetration of the occluded segment of the IVC from its distal to proximal end was performed through the femoral vein. Note. GGT ¼ g-glutamyl transpeptidase; TB ¼ total bilirubin; BUN ¼ blood urea nitrogen; INR ¼ international normalized ratio.
Step 3. Transcatheter thrombolysis. A 5F pigtail catheter or 5F thrombolytic catheter (Cook Medical, Bloomington, IN, USA) was inserted via the femoral vein or internal jugular vein, and the segment with side holes was located inside the thrombus. A pulse-spray infusion was used to inject 20 mL of saline and 10 million units of urokinase once every 3e6 hours. The thrombolytic catheter was kept in place, and angiography was performed 2 days later. Thrombolysis treatment was terminated if: (a) the thrombus was completely lysed; (b) during thrombolysis serious complications such as organ bleeding occurred; and (c) there was no change in the thrombus 2 days after thrombolysis treatment. During thrombolysis, 5000 U of low-molecular-weight heparin was injected subcutaneously every 12 hours. Thrombolysis was administered on a common ward. Fibrinogen, prothrombin time, and activated partial thromboplastin time were tested every 2 days during thrombolytic therapy.
Step 4. Large balloon dilation of the IVC. After thrombolytic treatment of mixed thrombus ( Fig. 2FeI ) and fresh thrombus (Fig. 3 ) or in patients with old thrombus (Fig. 4Ae  C) , a large balloon dilation of the IVC was performed. The balloons used were 20, 25, 26, or 28 mm in diameter and 40 mm in length (Optimed, Ettlingen, Germany) or 30 mm in diameter and 50 mm in length (Cook Medical).
Step 5. Self-expandable IVC stent placement. This was considered when: (a) after large balloon dilation of the IVC, luminal diameter retraction was greater than 50%; (b) after large balloon dilation of the IVC, the pressure gradient between the IVC and the right atrium was higher than 15 cm H 2 O (1 cmH 2 O ¼ 0.098 kPa); or (c) there were emboli in the IVC and stent compression was needed. A stainless steel Ztype IVC stent with a diameter of 28 or 30 mm and a length of 70e90 mm (Shenyang Yongtong Technology Co., Ltd., Shengyang, China) was used.
Post-treatment observations and follow-up
After treatment, all patients received subcutaneous lowmolecular-weight heparin for 4e7 days, followed by warfarin sodium for 12e24 months. The international normalized ratio (INR) was maintained at 2e3. Follow-up included determination of symptoms and signs, color Doppler ultrasound, and laboratory test results (coagulation function, liver and kidney function). Follow-up was generally performed at 1, 3, 6, and 12 months after treatment and yearly thereafter. If the patient felt discomfort, followup examination was performed at any time upon request.
Statistical analysis
All statistical analyses were performed using SPSS, version 16.0 (SPSS Inc., Chicago, IL, USA). Quantitative data were expressed as median (range), and between-group comparisons were performed using an independent-sample t-test or paired-sample t-test. Count data were expressed as a ratio (or percentage), and the chi-square test was used for comparisons. KaplaneMeier curves were used to calculate cumulative primary patency rates and cumulative secondary patency rates. A Cox proportional hazards regression model was used to analyze predictable risk factors for reocclusion. The factors that were statistically significant in univariate analysis (p < .05) were further tested with multivariate analysis. A difference with p < .05 was considered statistically significant. 
RESULTS
The overall success
The success rate of endovascular treatment in this study was 98.5% (131/133). The mean pressure gradient between the IVC and the right atrium dropped from 26 (range 18e 33) cmH 2 O before treatment to 8 (range 3e15) cmH 2 O after treatment (t ¼ 106.2, p < .05). Of the 74 patients with a fresh thrombus, the thrombus was completely lysed in 71 patients and partially lysed in three. Of the 19 patients with mixed thrombus, the thrombus was completely lysed in 14 patients and partially lysed in five (chi square ¼ 6.9, p < .05). Thirty-seven patients had synchronous hepatic vein occlusion, the accessory hepatic vein was patent in 16 patients, and one main hepatic vein was recanalized successfully in 21 patients. In 131 patients, the clinical manifestations were improved at discharge.
Technical failure
Technical failure occurred in two patients (1.5%). One patient with a fresh IVC thrombus developed a subarachnoid hemorrhage after the first transcatheter injection of 10 million units of urokinase. After 1 month, the patient had recovered from the brain hemorrhage. The second patient had an old, widely calcified IVC thrombus. After IVC penetration and placement of a 20-mm balloon for dilation, the balloon ruptured. No further endovascular treatment was performed.
Procedure-related complications
Six (4.5%) patients had serious complications. Three patients sustained symptomatic pulmonary embolisms after large balloon dilation and were treated successfully using urokinase. Two patients had cerebral hemorrhage. Subarachnoid hemorrhage occurred in one patient (as previously mentioned). In the second patient, a cerebellar hemorrhage occurred at the end of thrombolytic treatment. Anticoagulation and thrombolytic treatment were stopped after IVC balloon dilation. Two months later, the patient had completely recovered. One patient developed cardiac tamponade secondary to vascular manipulations. Pericardial drainage was achieved using a percutaneous catheter. There were three (2.3%) patients with mild complications. Two patients had a hematoma of the femoral vein puncture site and one had a hematoma of the jugular vein puncture site. Both patients responded to local compression.
Patency
The average duration of follow-up in the 131 patients was 46 (range 3e132) months. Ten patients were lost to follow up. Among the remaining 121 patients, the clinical manifestations had improved significantly in 104 patients and deteriorated in 17 ( Table 2 ). The duration of anticoagulant therapy in 41 patients was less than 6 months. Among the 35 patients in the old thrombus group, 21 had a complete resolution of their thrombus (Fig. 4D) . In 14 patients, the thrombus was reduced in size compared with pretreatment. Color Doppler ultrasound showed IVC lumen patency in 105 patients (86.8%), and IVC reocclusion in 16 patients (13.2%). The reocclusion rate was 14.5% (10/69), 11.8% (2/17), and 11.4% (4/35) in the fresh, mixed, and old thrombus groups respectively (chi square ¼ 0.2, p ¼ .9). In 16 patients with reocclusion, eight received another thrombolytic treatment before balloon dilation, and IVC patency was again achieved. Four patients received another balloon dilation and stent placement, and IVC patency was achieved as well. Endovascular treatment was not completed in four patients at their request. The cumulative 1-, 5-, and 10-year primary patency rate was 96.3%, 84.0% and 64.6%, respectively. The cumulative 1-, 5-, and 10-year secondary patency rate was 99.0%, 96.1% and 91.3%, respectively (Fig. 5) . Univariate analysis showed that alphafetoprotein (>20 ng/mL), prothrombin time (<17 seconds), INR (<1.5), segmental occlusion of IVC (>1 cm), and anticoagulant therapy <6 months were the risk factors for reocclusion, whereas gender, age, liver function, kidney function, absence of thrombolytic therapy (for old thrombosis), Childe 
DISCUSSION
In the present study, IVC thrombi were firstly divided into fresh, mixed, and old types, and different endovascular treatment strategies were adopted accordingly. A long-term follow-up of a large number of cases was carried out and satisfactory therapeutic outcomes were achieved. Mixed thrombi include a large amount of white thrombus and a small amount of red thrombus. White thrombus is rich in fibers and retracts more than red thrombus, and is, therefore, not easily lysed. 8 After small balloon pre-dilation of the IVC, blood flow towards the heart was restored, thereby improving the efficacy of thrombolytic treatment. In our study, none of the patients in the mixed thrombus group developed clinically significant pulmonary embolism. This indicates that small balloon pre-dilation is safe. In this study, the diameter of small balloons was 8e10 mm and after small balloon pre-dilation of the IVC, the lumen was significantly narrowed by more than 50%. This observation was similar to an IVC filter used to treat deep vein thrombosis of the lower limbs, 9 which could stop large thrombi. Even if the smaller fragments fell off, they did not result in symptomatic pulmonary embolism and subsequent thrombolytic therapy gradually lysed these fragments. There are several methods for treating BCS complicated by fresh IVC thrombus. They include thrombolytic therapy with drugs such as urokinase, rtPA, and agitation thrombolysis. 6, 10 In contrast to the previous reports, we successfully treated 74 patients with BCS complicated by fresh IVC thrombus using transcatheter thrombus aspiration in combination with pulse-spray thrombolysis. Consistent with our results, Yamada et al. 11 reported that pulse-spray thrombolysis was a safe and effective approach for treating acute deep venous thrombosis.
Methods used to treat BCS complicated by old IVC thrombus included thrombolytic therapy before IVC dilation, stent filter placement, and thrombolytic therapy after IVC dilation. 12, 13 In contrast to previous studies, 38 patients were successfully treated with direct large balloon dilation of the IVC and/or stent placement, followed by anticoagulant therapy with warfarin. Because old thrombus is firmly and closely adherent to the vessel wall and does not fall off, pulmonary embolism does not occur after opening the IVC. In addition, after IVC blood flow is restored to normal, the old thrombus will gradually undergo autolysis.
Previous studies have shown that balloon dilation and/or stent placement can achieve satisfactory long-term outcomes in BCS patients.
14e16 A study by Han et al. 14 showed that after vessel recanalization in BCS patients, the 1-, 5-, and 10-year cumulative primary patency rate was 95%, 77% and 58%, respectively, and the 1-, 5-, and 10-year cumulative secondary patency rate was 97%, 90% and 86%, respectively. The 1-, 5-, and 10-year cumulative primary patency rate and cumulative secondary patency rate observed in this study were similar to those reported by Han et al. Previous studies have shown that factors such as segmental occlusion of the IVC and no postoperative anticoagulant therapy are highly correlated with reocclusion. 15, 16 In this study segmental occlusion of the IVC and duration of anticoagulant therapy <6 months were highly correlated with reocclusion. A minority of patients did not achieve the anticoagulant effect, probably because they did not take the warfarin as prescribed. This might be one of the reasons why the duration of anticoagulant therapy was less than 6 months.
CONCLUSION
Patients with BCS complicated by IVC thrombosis should be managed on an individualized basis, according to the property of their thrombus (fresh, mixed, or old). Our results have shown that endovascular treatment for patients with BCS complicated by IVC thrombosis is safe and feasible, and can achieve excellent long-term patency.
